



US009320904B2

(12) **United States Patent**
Whiting et al.

(10) **Patent No.:** **US 9,320,904 B2**
(45) **Date of Patent:** **Apr. 26, 2016**

(54) **MEDICAL MONITORING AND TREATMENT DEVICE WITH EXTERNAL PACING**

(71) Applicant: **ZOLL MEDICAL CORPORATION**, Chelmsford, MA (US)

(72) Inventors: **Jason T. Whiting**, Gibsonia, PA (US); **Thomas E. Kaib**, Irwin, PA (US); **Rachel H. Carlson**, Falls Creek, PA (US); **Gregory R. Frank**, Mt. Lebanon, PA (US)

(73) Assignee: **ZOLL MEDICAL CORPORATION**, Chelmsford, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/610,600**

(22) Filed: **Jan. 30, 2015**

(65) **Prior Publication Data**

US 2015/0148854 A1 May 28, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/907,523, filed on May 31, 2013, now Pat. No. 8,983,597.

(60) Provisional application No. 61/653,889, filed on May 31, 2012.

(51) **Int. Cl.**

- A61N 1/00* (2006.01)
- A61N 1/365* (2006.01)
- A61N 1/362* (2006.01)
- A61N 1/39* (2006.01)
- A61B 5/00* (2006.01)
- A61B 5/0408* (2006.01)
- A61B 5/046* (2006.01)
- A61N 1/04* (2006.01)

(52) **U.S. Cl.**

CPC *A61N 1/36592* (2013.01); *A61B 5/046* (2013.01); *A61B 5/04085* (2013.01); *A61B 5/6831* (2013.01); *A61N 1/046* (2013.01); *A61N 1/0484* (2013.01); *A61N 1/362* (2013.01); *A61N1/3625* (2013.01); *A61N 1/3925* (2013.01); *A61N 1/3987* (2013.01)

(58) **Field of Classification Search**

CPC A61N 1/3625; A61N 1/365; A61N 1/39
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,094,310 A 6/1978 McEachern et al.
4,393,874 A 7/1983 Nappholz et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0295497	B1	9/1993
EP	0335356	B1	3/1996
EP	1455640	B1	1/2008
EP	1720446	B1	7/2010
JP	5115450	A	5/1993
JP	2002200059	A	7/2002
WO	0002484	A1	1/2000
WO	2004054656	A1	7/2004
WO	2006050325	A1	5/2006
WO	2007057169	A1	5/2007
WO	2007077997	A1	7/2007
WO	2010025432	A1	3/2010

OTHER PUBLICATIONS

American Journal of Respiratory and Critical Care Medicine, vol. 166, pp. 111-117 (2002). American Thoracic Society, ATS Statement Guidelines for the Six-Minute Walk Test, available at <http://ajrcm.atsjournals.org/cgi/content/full/166/1/111>.

(Continued)


Primary Examiner — Robert N Wieland

(74) Attorney, Agent, or Firm — Lando & Anastasi, LLP

(57) **ABSTRACT**

A non-invasive bodily-attached ambulatory medical monitoring and treatment device with pacing is provided. The non-invasive ambulatory pacing device includes a battery, at least one therapy electrode coupled to the battery, a memory storing information indicative of a patient's cardiac activity, and at least one processor coupled to the memory and the at least one therapy electrode. The at least one processor is configured to identify a cardiac arrhythmia within the information and execute at least one pacing routine to treat the identified cardiac arrhythmia.

23 Claims, 4 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

- | | | | | | | | |
|--------------|----|---------|---------------------|--------------|-----|---------|------------------------------------|
| 4,632,122 | A | 12/1986 | Johansson et al. | 2006/0178706 | A1 | 8/2006 | Lisogurski et al. |
| 4,928,690 | A | 5/1990 | Heilman et al. | 2006/0220809 | A1 | 10/2006 | Stigall et al. |
| 4,978,926 | A | 12/1990 | Zerod et al. | 2006/0264776 | A1 | 11/2006 | Stahmann et al. |
| 5,062,834 | A | 11/1991 | Gross et al. | 2006/0270952 | A1 | 11/2006 | Freeman et al. |
| 5,078,134 | A | 1/1992 | Heilman et al. | 2007/0073120 | A1 | 3/2007 | Li et al. |
| 5,205,284 | A | 4/1993 | Freeman | 2007/0118056 | A1 | 5/2007 | Wang et al. |
| 5,282,843 | A | 2/1994 | Freeman | 2007/0161913 | A1 | 7/2007 | Farrell et al. |
| 5,330,505 | A | 7/1994 | Cohen | 2007/0169364 | A1 | 7/2007 | Townsend et al. |
| 5,348,008 | A | 9/1994 | Bornn et al. | 2007/0239220 | A1 | 10/2007 | Greenhut et al. |
| 5,357,696 | A | 10/1994 | Gray et al. | 2007/0265671 | A1 | 11/2007 | Roberts et al. |
| 5,365,932 | A | 11/1994 | Greenhut | 2008/0004536 | A1 | 1/2008 | Baxi et al. |
| 5,431,688 | A | 7/1995 | Freeman | 2008/0030656 | A1 | 2/2008 | Watson et al. |
| 5,662,689 | A | 9/1997 | Elsberry et al. | 2008/0031270 | A1 | 2/2008 | Tran et al. |
| 5,718,242 | A | 2/1998 | McClure et al. | 2008/0033495 | A1 | 2/2008 | Kumar |
| 5,738,102 | A | 4/1998 | Lemelson | 2008/0045815 | A1 | 2/2008 | Derchak et al. |
| 5,741,306 | A | 4/1998 | Glegyak et al. | 2008/0058884 | A1 | 3/2008 | Matos |
| 5,758,443 | A | 6/1998 | Pedrazzini | 2008/0249591 | A1 | 10/2008 | Gaw et al. |
| 5,792,190 | A | 8/1998 | Olson et al. | 2008/0306562 | A1 | 12/2008 | Donnelly et al. |
| 5,797,967 | A | 8/1998 | KenKnight | 2009/0073991 | A1 | 3/2009 | Landrum et al. |
| 5,929,601 | A | 7/1999 | Kaib et al. | 2009/0076336 | A1 | 3/2009 | Mazar et al. |
| 5,944,669 | A | 8/1999 | Kaib | 2009/0076340 | A1 | 3/2009 | Libbus et al. |
| 6,016,445 | A | 1/2000 | Baura | 2009/0076341 | A1 | 3/2009 | James et al. |
| 6,045,503 | A | 4/2000 | Grabner et al. | 2009/0076342 | A1 | 3/2009 | Amurthur et al. |
| 6,058,328 | A | 5/2000 | Levine et al. | 2009/0076343 | A1 | 3/2009 | James et al. |
| 6,065,154 | A | 5/2000 | Hulings et al. | 2009/0076344 | A1 | 3/2009 | Libbus et al. |
| 6,097,987 | A | 8/2000 | Milani | 2009/0076345 | A1 | 3/2009 | Manicka et al. |
| 6,148,233 | A | 11/2000 | Owen et al. | 2009/0076346 | A1 | 3/2009 | James et al. |
| 6,169,387 | B1 | 1/2001 | Kaib | 2009/0076348 | A1 | 3/2009 | Manicka et al. |
| 6,169,397 | B1 | 1/2001 | Steinbach et al. | 2009/0076349 | A1 | 3/2009 | Libbus et al. |
| 6,253,099 | B1 | 6/2001 | Oskin et al. | 2009/0076350 | A1 | 3/2009 | Bly et al. |
| 6,280,461 | B1 | 8/2001 | Glegyak et al. | 2009/0076363 | A1 | 3/2009 | Bly et al. |
| 6,390,996 | B1 | 5/2002 | Halperin et al. | 2009/0076364 | A1 | 3/2009 | Libbus et al. |
| 6,406,426 | B1 | 6/2002 | Reuss et al. | 2009/0076397 | A1 | 3/2009 | Libbus et al. |
| 6,681,003 | B2 | 1/2004 | Linder et al. | 2009/0076405 | A1 | 3/2009 | Amurthur et al. |
| 6,690,969 | B2 | 2/2004 | Bystrom et al. | 2009/0076410 | A1 | 3/2009 | Libbus et al. |
| 6,804,554 | B2 | 10/2004 | Ujhelyi et al. | 2009/0076559 | A1 | 3/2009 | Libbus et al. |
| 6,827,695 | B2 | 12/2004 | Palazzolo et al. | 2009/0093687 | A1 | 4/2009 | Telfort et al. |
| 6,865,413 | B2 | 3/2005 | Halperin et al. | 2009/0138059 | A1 | 5/2009 | Ouwerkerk |
| 6,889,078 | B2 | 5/2005 | Struble et al. | 2009/0234410 | A1 | 9/2009 | Libbus et al. |
| 6,889,079 | B2 | 5/2005 | Bocek et al. | 2009/0264792 | A1 | 10/2009 | Mazar |
| 6,908,437 | B2 | 6/2005 | Bardy | 2009/0275848 | A1 | 11/2009 | Brockway et al. |
| 6,990,373 | B2 | 1/2006 | Jayne et al. | 2009/0287120 | A1 | 11/2009 | Ferren et al. |
| 7,074,199 | B2 | 7/2006 | Halperin et al. | 2009/0292194 | A1 | 11/2009 | Libbus et al. |
| 7,108,665 | B2 | 9/2006 | Halperin et al. | 2010/0056881 | A1 | 3/2010 | Libbus et al. |
| 7,118,542 | B2 | 10/2006 | Palazzolo et al. | 2010/0069735 | A1 | 3/2010 | Berkner |
| 7,122,014 | B2 | 10/2006 | Palazzolo et al. | 2010/0076513 | A1 | 3/2010 | Warren et al. |
| 7,130,690 | B2 | 10/2006 | Rueter et al. | 2010/0234716 | A1 | 9/2010 | Engel |
| 7,149,579 | B1 | 12/2006 | Koh et al. | 2010/0295674 | A1 | 11/2010 | Hsieh et al. |
| 7,220,235 | B2 | 5/2007 | Geheb et al. | 2010/0298899 | A1 | 11/2010 | Donnelly et al. |
| 7,295,871 | B2 | 11/2007 | Halperin et al. | 2010/0312297 | A1 | 12/2010 | Volpe et al. |
| 7,340,296 | B2 | 3/2008 | Stahmann et al. | 2011/0022105 | A9 | 1/2011 | Owen et al. |
| 7,427,921 | B2 | 9/2008 | Van Woudenberg | 2011/0288604 | A1 | 11/2011 | Kaib et al. |
| 7,453,354 | B2 | 11/2008 | Reiter et al. | 2011/0288605 | A1 | 11/2011 | Kaib et al. |
| 7,476,206 | B2 | 1/2009 | Palazzolo et al. | 2012/0011382 | A1 | 1/2012 | Volpe et al. |
| 7,488,293 | B2 | 2/2009 | Marcovecchio et al. | 2012/0112903 | A1 | 5/2012 | Kaib et al. |
| 7,831,303 | B2 | 11/2010 | Rueter et al. | 2012/0146797 | A1 | 6/2012 | Oskin et al. |
| 7,974,689 | B2 | 7/2011 | Volpe et al. | 2012/0150244 | A1* | 6/2012 | Freeman A61H 31/005
607/3 |
| 8,121,683 | B2 | 2/2012 | Bucher et al. | 2012/0158075 | A1 | 6/2012 | Kaib et al. |
| 8,140,154 | B2 | 3/2012 | Donnelly et al. | 2013/0338724 | A1 | 12/2013 | Joo et al. |
| 8,271,082 | B2 | 9/2012 | Donnelly et al. | 2014/0364918 | A1* | 12/2014 | Owen A61N 1/0452
607/6 |
| 2003/0004547 | A1 | 1/2003 | Owen et al. | | | | |
| 2003/0095648 | A1 | 5/2003 | Kaib et al. | | | | |
| 2003/0149462 | A1 | 8/2003 | White et al. | | | | |
| 2003/0158593 | A1 | 8/2003 | Heilman et al. | | | | |
| 2003/0174049 | A1 | 9/2003 | Beigel et al. | | | | |
| 2003/0195567 | A1 | 10/2003 | Jayne et al. | | | | |
| 2003/0212311 | A1 | 11/2003 | Nova et al. | | | | |
| 2004/0007970 | A1 | 1/2004 | Ma et al. | | | | |
| 2004/0049233 | A1 | 3/2004 | Edwards | | | | |
| 2005/0049515 | A1 | 3/2005 | Misczynski et al. | | | | |
| 2005/0131465 | A1 | 6/2005 | Freeman et al. | | | | |
| 2006/0036292 | A1 | 2/2006 | Smith et al. | | | | |
| 2006/0085049 | A1 | 4/2006 | Cory et al. | | | | |

OTHER PUBLICATIONS

- DeBock et al., "Captopril treatment of chronic heart failure in the very old," *J. Gerontol.* (1994) 49: M148-M152.
- Internation Search Report and Written Opinion from corresponding PCT application PCT/US2013/043736, dated Sep. 4, 2013.
- O'Keefe et al., "Reproducibility and responsiveness of quality of the assessment and six minute walk test in elderly heart failure patients," *Heart* (1998) 80: 377-382.
- Reek et al. Clinical Efficacy of a Wearable Defibrillator Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shock.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4

MEDICAL MONITORING AND TREATMENT DEVICE WITH EXTERNAL PACING

RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §120 as a continuation of U.S. application Ser. No. 13/907,523 titled "MEDICAL MONITORING AND TREATMENT DEVICE WITH EXTERNAL PACING" filed on May 31, 2013, now U.S. Pat. No. 8,983,597, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Ser. No. 61/653,889, titled "NONINVASIVE AMBULATORY MONITORING AND TREATMENT DEVICE WITH EXTERNAL PACING," filed on May 31, 2012, each of which is hereby incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Technical Field

The present invention is directed to noninvasive ambulatory medical devices, and more particularly, to a non-invasive medical monitoring and treatment device that is capable of externally pacing the heart of a patient wearing the device.

2. Discussion of the Related Art

Cardiac arrest and other cardiac health ailments are a major cause of death worldwide. Various resuscitation efforts aim to maintain the body's circulatory and respiratory systems during cardiac arrest in an attempt to save the life of the victim. The sooner these resuscitation efforts begin, the better the victim's chances of survival.

To protect against cardiac arrest and other cardiac health ailments, some at-risk patients may use a wearable defibrillator, such as the LifeVest® wearable cardioverter defibrillator available from ZOLL Medical Corporation of Chelmsford, Mass. To remain protected, the patient wears the device nearly continuously while going about their normal daily activities, while awake, and while asleep.

SUMMARY OF THE INVENTION

Some aspects and embodiments of the present invention administer external pacing to the heart using a non-invasive bodily-attached ambulatory medical monitoring and treatment device (hereinafter referred to as a "medical monitoring and treatment device"). As used herein, the term non-invasive means that the device does not penetrate the body of a patient. This is in contrast to invasive devices, such as implantable medical devices, in which at least a portion of the device is disposed subcutaneously. The term bodily-attached means that at least a portion of the device (other than its electrodes in the case of a defibrillator, cardioverter or pacer) is removably attached to the body of a patient, such as by mechanical coupling (for example, by a wrist strap, cervical collar, bicep ring), adhesion (for example, by an adhesive gel intermediary), suction, magnetism, fabric or other flexible material (for example, by straps or integration into a garment) or other body mounting features not limited by the aforementioned examples. These coupling elements hold the device in a substantially fixed position with respect to the body of the patient. The term ambulatory means that the device is capable of and designed for moving with the patient as the patient goes about their daily routine.

One example of a medical monitoring and treatment device is the LifeVest® Wearable Cardioverter Defibrillator available from ZOLL Medical Corporation of Chelmsford, Mass. A medical monitoring and treatment device can provide life

saving defibrillation treatment to a patient suffering a treatable form of cardiac arrhythmia such as Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT). Applicants have appreciated that such a medical monitoring and treatment device can be configured to perform a variety of different types of cardiac pacing to treat a wide variety of different cardiac arrhythmias, such as bradycardia, tachycardia, an irregular cardiac rhythm, and asystole (including asystole after a shock). Applicants have further appreciated that, in other embodiments, a medical monitoring and treatment device can be configured to perform pacing to treat pulseless electrical activity. In accordance with an aspect of the present invention, the medical monitoring and treatment device can be configured to pace the heart of the patient at a fixed energy level (e.g., fixed current, fixed voltage, etc. . . .) and pulse rate, to pace the heart of the patient on demand with a fixed energy level and an adjustable rate responsive to the detected intrinsic activity level of the patient's heart, or to pace the heart of the patient using capture management with an adjustable energy level and adjustable rate responsive to the detected intrinsic rate of the patient's heart and the detected response of the patient's heart to pacing, including both on a beat-by-beat basis and as analyzed over other various time intervals.

According to some embodiments, a medical monitoring and treatment device is provided. The medical monitoring and treatment device includes a battery, at least one therapy electrode coupled to the battery, a memory storing information indicative of a patient's cardiac activity, and at least one processor coupled to the memory and the at least one therapy electrode. The at least one processor is configured to identify a cardiac arrhythmia within the information and execute at least one pacing routine to treat the identified cardiac arrhythmia.

In the medical monitoring and treatment device, the cardiac arrhythmia that the at least one processor is configured to identify may include bradycardia and the at least one pacing routine may be configured to determine that a first interval has passed without detection of a heart beat and apply, responsive to determining that the first interval has passed, a pacing pulse via the at least one therapy electrode. The first interval may be defined by a base pacing rate and a hysteresis rate. The at least one pacing routine may be further configured to detect an intrinsic heart beat prior to passage of a second interval; determine a third interval based on the base pacing rate, the hysteresis rate, and a point where the intrinsic heart beat was detected; and determine whether another intrinsic heart beat occurs within the third interval.

In the medical monitoring and treatment device, the cardiac arrhythmia that the at least one processor is configured to identify may include tachycardia and the at least one pacing routine may be configured to detect a plurality of intrinsic heart beats prior to passage of a first interval, the plurality of intrinsic heart beats having an intrinsic frequency, the first interval being defined by an anti-tachyarrhythmic pacing rate and apply, responsive to detecting the intrinsic frequency, a series of pacing pulses via the at least one therapy electrode, the series of pacing pulses having a frequency above the intrinsic frequency. The at least one pacing routine may be further configured to detect, after applying the series of pacing pulses, whether another plurality of intrinsic heart beats occur within a second interval, the second interval being defined by the anti-tachyarrhythmic pacing rate.

In the medical monitoring and treatment device, the cardiac arrhythmia that the at least one processor is configured to identify may include an erratic heart rate and the at least one pacing routine may be configured to identify a first series of heart beats within the information, the first series having a

lower frequency; identify a second series of heart beats within the information, the second series a upper frequency; and apply, responsive to identifying the erratic heart rate, a series of pacing pulses via the at least one therapy electrode, the series of pacing pulses having a frequency above the lower frequency and below the upper frequency.

In the medical monitoring and treatment device, the cardiac arrhythmia that the at least one processor is configured to identify may include at least one of asystole and pulseless electrical activity and the at least one pacing routine may be configured to determine that a first interval has passed without detection of a heart beat; and apply, responsive to determining that the first interval has passed, a pacing pulse via the at least one therapy electrode. The at least one pacing routine may be further configured to apply a defibrillating shock prior to applying the pacing pulse.

In the medical monitoring and treatment device, the at least one pacing routine may be further configured to determine whether the at least one pacing routine resulted in capture and adjust, responsive to determining that capture did not result, the characteristics of pacing pulses applied during subsequent executions of the at least one pacing routine. The characteristics of the pacing pulses subject to adjustment may include a pulse energy level, a pulse rate, and a pulse width.

In the medical monitoring and treatment device, the at least one pacing routine is further configured to determine whether the at least one pacing routine resulted in capture; and adjust, responsive to determining that capture did result, the characteristics of pacing pulses applied during subsequent executions of the at least one pacing routine.

According to other embodiments, a non-invasive bodily-attached ambulatory wearable defibrillator is provided. The non-invasive bodily-attached ambulatory wearable defibrillator includes a battery, at least one therapy electrode coupled to the battery, a memory storing information indicative of a patient's cardiac activity, and at least one processor coupled to the memory and the at least one therapy electrode. The at least one processor is configured to identify a cardiac arrhythmia within the information and execute at least one pacing routine to treat the identified cardiac arrhythmia.

In the non-invasive bodily-attached ambulatory defibrillator, the cardiac arrhythmia that the at least one processor is configured to identify may include bradycardia and the at least one pacing routine may be configured to determine that a first interval has passed without detection of a heart beat and apply, responsive to determining that the first interval has passed, a pacing pulse via the at least one therapy electrode. The first interval may be defined by a base pacing rate and a hysteresis rate. The at least one pacing routine may be further configured to detect an intrinsic heart beat prior to passage of a second interval; determine a third interval based on the base pacing rate, the hysteresis rate, and a point where the intrinsic heart beat was detected; and determine whether another intrinsic heart beat occurs within the third interval.

In the non-invasive bodily-attached ambulatory defibrillator, the cardiac arrhythmia that the at least one processor is configured to identify may include tachycardia and the at least one pacing routine may be configured to detect a plurality of intrinsic heart beats prior to passage of a first interval, the plurality of intrinsic heart beats having an intrinsic frequency, the first interval being defined by an anti-tachyarrhythmic pacing rate; and apply, responsive to detecting the intrinsic frequency, a series of pacing pulses via the at least one therapy electrode, the series of pacing pulses having a frequency above the intrinsic frequency. The at least one pacing routine may be further configured to detect, after applying the series of pacing pulses, whether another plurality of intrinsic heart

beats occur within a second interval, the second interval being defined by the anti-tachyarrhythmic pacing rate.

In the non-invasive bodily-attached ambulatory defibrillator, the cardiac arrhythmia that the at least one processor is configured to identify may include an erratic heart rate and the at least one pacing routine may be configured to identify a first series of heart beats within the information, the first series having a lower frequency; identify a second series of heart beats within the information, the second series a upper frequency; and apply, responsive to identifying the erratic heart rate, a series of pacing pulses via the at least one therapy electrode, the series of pacing pulses having a frequency above the lower frequency and below the upper frequency.

In the non-invasive bodily-attached ambulatory defibrillator, the cardiac arrhythmia that the at least one processor is configured to identify may include at least one of asystole and pulseless electrical activity and the at least one pacing routine may be configured to determine that a first interval has passed without detection of a heart beat and apply, responsive to determining that the first interval has passed, a pacing pulse via the at least one therapy electrode. The at least one pacing routine may be further configured to apply a defibrillating shock prior to applying the pacing pulse.

In the non-invasive bodily-attached ambulatory defibrillator, the at least one pacing routine may be further configured to determine whether the at least one pacing routine resulted in capture and adjust, responsive to determining that capture did not result, the characteristics of pacing pulses applied during subsequent executions of the at least one pacing routine. The characteristics of the pacing pulses subject to adjustment may include a pulse energy level, a pulse rate, and a pulse width.

In the non-invasive bodily-attached ambulatory defibrillator, the at least one pacing routine may be further configured to determine whether the at least one pacing routine resulted in capture and adjust, responsive to determining that capture did result, the characteristics of pacing pulses applied during subsequent executions of the at least one pacing routine.

According to another embodiment, a method of treating cardiac dysfunction using a medical monitoring and treatment device with pacing is provided. The medical monitoring and treatment device may include a non-invasive bodily-attached ambulatory defibrillator. The method includes acts of identifying, by the medical monitoring and treatment device, a cardiac arrhythmia within information indicative of a patient's cardiac activity; and executing, by the medical monitoring and treatment device, at least one pacing routine to treat the identified cardiac arrhythmia.

In the method, where the cardiac arrhythmia includes bradycardia, the act of executing the at least one pacing routine may include acts of determining that a first interval has passed without detection of a heart beat and applying, responsive to determining that the first interval has passed, a pacing pulse via the at least one therapy electrode. The act of determining that the first interval has passed may include an act of defining the first interval using a base pacing rate and a hysteresis rate. The act of executing the at least one pacing routine may include acts of detecting an intrinsic heart beat prior to passage of a second interval; determining a third interval based on the base pacing rate, the hysteresis rate, and a point where the intrinsic heart beat was detected; and determining whether another intrinsic heart beat occurs within the third interval.

In the method, where the cardiac arrhythmia includes tachycardia, the act of executing the at least one pacing routine may include acts of detecting a plurality of intrinsic heart beats prior to passage of a first interval, the plurality of intrinsic

sic heart beats having an intrinsic frequency, the first interval being defined by an anti-tachyarrhythmic pacing rate and applying, responsive to detecting the intrinsic frequency, a series of pacing pulses via the at least one therapy electrode, the series of pacing pulses having a frequency above the intrinsic frequency.

In the method, where the cardiac arrhythmia includes an erratic heart rate, the act of executing the at least one pacing routine may include acts of identifying a first series of heart beats within the information, the first series having a lower frequency; identifying a second series of heart beats within the information, the second series a upper frequency; and applying, responsive to identifying the erratic heart rate, a series of pacing pulses via the at least one therapy electrode, the series of pacing pulses having a frequency above the lower frequency and below the upper frequency.

In the method, where the cardiac arrhythmia includes at least one of asystole and pulseless electrical activity, the act of executing the at least one pacing routine may include acts of determining that a first interval has passed without detection of a heart beat; and applying, responsive to determining that the first interval has passed, a pacing pulse via the at least one therapy electrode. The act of executing the at least one pacing routine may include an act of applying a defibrillating shock prior to applying the pacing pulse.

In the method, the act of executing the at least one pacing routine may include acts of determining whether the at least one pacing routine resulted in successful capture and adjusting, responsive to determining that capture did not result, the characteristics of pacing pulses applied during subsequent executions of the at least one pacing routine. The act of adjusting the characteristics may include an act of adjusting at least one of a pulse energy level, a pulse rate, and a pulse width.

Still other aspects, embodiments, and advantages of these exemplary aspects and embodiments are discussed in detail below. Moreover, it is to be understood that both the foregoing information and the following detailed description are merely illustrative examples of various aspects and embodiments of the present invention, and are intended to provide an overview or framework for understanding the nature and character of the claimed aspects and embodiments. Any embodiment disclosed herein may be combined with any other embodiment in any manner consistent with at least one of the aspects disclosed herein, and references to "an embodiment," "some embodiments," "an alternate embodiment," "various embodiments," "one embodiment," "at least one embodiment," "this and other embodiments" or the like are not necessarily mutually exclusive and are intended to indicate that a particular feature, structure, or characteristic described in connection with the embodiment may be included in at least one embodiment. The appearance of such terms herein is not necessarily all referring to the same embodiment.

Furthermore, in the event of inconsistent usages of terms between this document and documents incorporated herein by reference, the term usage in the incorporated references is supplementary to that of this document; for irreconcilable inconsistencies, the term usage in this document controls. In addition, the accompanying drawings are included to provide illustration and a further understanding of the various aspects and embodiments, and are incorporated in and constitute a part of this specification. The drawings, together with the remainder of the specification, serve to explain principles and operations of the described and claimed aspects and embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical

component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:

FIG. 1 illustrates a medical monitoring and treatment device, such as a wearable defibrillator;

FIG. 2 is a functional block diagram of one example of a portable treatment controller that may be used in the medical monitoring and treatment device of FIG. 1;

FIG. 3 illustrates a number of different pacing waveforms that may be provided by the medical monitoring and treatment device, including a 40 ms constant current pulse; and

FIG. 4 illustrates various aspects of demand pacing which can be adjusted in connection with on demand pacing or capture management pacing.

DETAILED DESCRIPTION

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," "having," "containing," "involving," and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

FIG. 1 illustrates a medical monitoring and treatment device, such as a LifeVest® Wearable Cardioverter Defibrillator available from ZOLL Medical Corporation of Chelmsford, Mass. As shown, the medical monitoring and treatment device **100** includes a harness **110** having a pair of shoulder straps and a belt that is worn about the torso of a patient. The harness **110** is typically made from a material, such as cotton, nylon, spandex, or antron that is breathable, and unlikely to cause skin irritation, even when worn for prolonged periods of time. The medical monitoring and treatment device **100** includes a plurality of electrocardiographic (ECG) sensing electrodes **112** that are disposed by the harness **110** at various positions about the patient's body and electrically coupled (wirelessly or by a wired connection) to a portable treatment controller **120** via a connection pod **130**. The plurality of ECG sensing electrodes **112** are used by the portable treatment controller **120** to monitor the cardiac function of the patient and generally include a front/back pair of ECG sensing electrodes and a side/side pair of ECG sensing electrodes. It should be appreciated that additional ECG sensing electrodes may be provided, and the plurality of ECG sensing electrodes **112** may be disposed at varying locations about the patient's body. In addition, the plurality of ECG electrodes **112** may incorporate any electrode system, including conventional stick-on adhesive electrodes, dry-sensing capacitive ECG electrodes, radio transparent electrodes, segmented electrodes, or one or more long term wear electrodes that are configured to be continuously worn by a patient for extended periods (e.g., 3 or more days). One example of such a long term wear electrode is described in co-pending Application Ser. No. 61/653,749, titled "LONG TERM WEAR MULTI-FUNCTION BIOMEDICAL ELECTRODE," filed May 31, 2012, which is hereby incorporated herein by reference in its entirety.

The medical monitoring and treatment devices disclosed herein may incorporate sundry materials arranged in a variety of configurations to maintain a proper fit with the patient's body. For example, some embodiments include a garment as described in co-pending application Ser. No. 13/460,250,

titled "PATIENT-WORN ENERGY DELIVERY APPARATUS AND TECHNIQUES FOR SIZING SAME," filed Apr. 30, 2012, which is hereby incorporated herein by reference in its entirety. Thus embodiments are not limited to the configuration and materials described above with reference to FIG. 1.

The medical monitoring and treatment device **100** also includes a plurality of therapy electrodes **114** that are electrically coupled to the portable treatment controller **120** via the connection pod **130** and which are capable of delivering one or more therapeutic defibrillating shocks to the body of the patient, if it is determined that such treatment is warranted. As shown, the plurality of therapy electrodes **114** includes a first therapy electrode **114a** that is disposed on the front of the patient's torso and a second therapy electrode **114b** that is disposed on the back of the patient's torso. The second therapy electrode **114b** includes a pair of therapy electrodes that are electrically coupled together and act as the second therapy electrode **114b**. The use of two therapy electrodes **114a**, **114b** permits a biphasic shock to be delivered to the body of the patient, such that a first of the two therapy electrodes can deliver a first phase of the biphasic shock with the other therapy electrode acting as a return, and the other therapy electrode can deliver the second phase of the biphasic shock with the first therapy electrode acting as the return. The connection pod **130** electrically couples the plurality of ECG sensing electrodes **112** and the plurality of therapy electrodes **114** to the portable treatment controller **120**, and may include electronic circuitry. For example, in one implementation the connection pod **130** includes signal acquisition circuitry, such as a plurality of differential amplifiers to receive ECG signals from different ones of the plurality of ECG sensing electrodes **112** and to provide a differential ECG signal to the portable treatment controller **120** based on the difference therebetween. The connection pod **130** may also include other electronic circuitry, such as a motion sensor or accelerometer by which patient activity may be monitored.

In some embodiments, both the first therapy electrode **114a** and the second therapy electrode **114b** are disposed on the front of the patient's torso. For example, the first therapy electrode **114a** may be located at external to the apex of the heart and the second therapy electrode **114b** may be located along the parasternal line. Thus embodiments are not limited to a particular arrangement of therapy electrodes **114**.

In some embodiments, the plurality of ECG sensing electrodes **112** are positioned and paired such that artifacts generated from electrical activity are decreased. In other embodiments, the electronic circuitry included in the portable treatment controller **120** may equalize artifacts measured at electrodes by changing a gain or impedance. Other techniques of decreasing or preventing artifacts within measured electrical activity that may be used in conjunction the embodiments disclosed herein are explained in U.S. Pat. No. 8,185,199, titled "MONITORING PHYSIOLOGICAL SIGNALS DURING EXTERNAL ELECTRICAL STIMULATION," issued May 22, 2012, which is incorporated by reference herein in its entirety.

As shown in FIG. 1, the medical monitoring and treatment device **100** may also include a user interface pod **140** that is electrically coupled to the portable treatment controller **120**. The user interface pod **140** can be attached to the patient's clothing or to the harness **110**, for example, via a clip (not shown) that is attached to a portion of the interface pod **140**. Alternatively, the user interface pod **140** may simply be held in a person's hand. The user interface pod **140** typically includes one or more actionable user interface elements (e.g., one or more buttons, a fingerprint scanner, a touch screen, microphone, etc. . . .) by which the patient, or a bystander can

communicate with the portable treatment controller **120**, and a speaker by which the portable treatment controller **120** may communicate with the patient or the bystander. In certain models of the LifeVest® Wearable Cardioverter Defibrillator, the functionality of the user interface pod **140** is incorporated into the portable treatment controller **120**.

Where the portable treatment controller **120** determines that the patient is experiencing cardiac arrhythmia, the portable treatment controller **120** may issue an audible alarm via a loudspeaker (not shown) on the portable treatment controller **120** and/or the user interface pod **140** alerting the patient and any bystanders to the patient's medical condition. Examples of notifications issued by the portable treatment controller **120** are described in co-pending application Ser. No. 13/428,703, titled "SYSTEM AND METHOD FOR ADAPTING ALARMS IN A WEARABLE MEDICAL DEVICE," filed Mar. 23, 2012, which is incorporated by reference herein in its entirety. The portable treatment controller **120** may also instruct the patient to press and hold one or more buttons on the portable treatment controller **120** or on the user interface pod **140** to indicate that the patient is conscious, thereby instructing the portable treatment controller **120** to withhold the delivery of one or more therapeutic defibrillating shocks. If the patient does not respond, the device may presume that the patient is unconscious, and proceed with the treatment sequence, culminating in the delivery of one or more defibrillating shocks to the body of the patient.

The portable treatment controller **120** generally includes at least one processor, microprocessor, or controller, such as a processor commercially available from companies such as Texas Instruments, Intel, AMD, Sun, IBM, Motorola, Freescale and ARM Holdings. In one implementation, the at least one processor includes a power conserving processor arrangement that comprises a general purpose processor, such as an Intel® PXA270 processor and a special purpose processor, such as a Freescale DSP56311 Digital Signal Processor. Such a power conserving processor arrangement is described in co-pending application Ser. No. 12/833,096, titled SYSTEM AND METHOD FOR CONSERVING POWER IN A MEDICAL DEVICE, filed Jul. 9, 2010 (hereinafter the "'096 application") which is incorporated by reference herein in its entirety. The at least one processor of the portable treatment controller **120** is configured to monitor the patient's medical condition, to perform medical data logging and storage, and to provide medical treatment to the patient in response to a detected medical condition, such as cardiac arrhythmia.

Although not shown, the medical monitoring and treatment device **100** may include additional sensors, other than the ECG sensing electrodes **112**, capable of monitoring the physiological condition or activity of the patient. For example, sensors capable of measuring blood pressure, heart rate, heart sounds, thoracic impedance, pulse oxygen level, respiration rate, and the activity level of the patient may also be provided.

FIG. 2 illustrates a portable treatment controller **120** that is configured to perform the critical functions of monitoring physiological information for abnormalities and initiating treatment of detected abnormalities. As shown, the portable treatment controller **120** can include the power conserving processor arrangement **200** described in the '096 application, a sensor interface **212**, a therapy delivery interface **202**, data storage **204**, a communication network interface **206**, a user interface **208** and a battery **210**. In this illustrated example, the battery **210** is a rechargeable 3 cell 2200 mAh lithium ion battery pack that provides electrical power to the other device

components with a minimum 24 hour runtime between charges. Such a battery 210 has sufficient capacity to administer one or more therapeutic shocks and the therapy delivery interface 202 has wiring suitable to carry the load to the therapy electrodes 114. Moreover, in the example shown, the battery 210 has sufficient capacity to deliver up to 5 or more therapeutic shocks, even at battery runtime expiration. The amount of power capable of being delivered to a patient during a defibrillating shock is substantial, for example up to approximately 200 Joules.

The sensor interface 212 and the therapy delivery interface 202 are coupled to the power conserving processor arrangement 200 and more particularly to the critical purpose processor of the power conserving processing arrangement 200 as described in the '096 application. The data storage 204, the network interface 206, and the user interface 208 are also coupled to the power conserving processor arrangement 200, and more particularly to the general purpose processor of the power conserving processing arrangement as also described in the '096 application.

In the example shown, the data storage 204 includes a computer readable and writeable nonvolatile data storage medium configured to store non-transitory instructions and other data. The medium may, for example, be optical disk, magnetic disk or flash memory, among others and may be permanently affixed to, or removable from, the portable treatment controller 120.

As shown in FIG. 2, the portable treatment controller 120 includes several system interface components 202, 206 and 212. Each of these system interface components is configured to exchange, i.e., send or receive data, with specialized devices that may be located within the portable treatment controller 200 or elsewhere. The components used by the interfaces 202, 206 and 212 may include hardware components, software components or a combination of both. In the instance of each interface, these components physically and logically couple the portable treatment controller 200 to one or more specialized devices. This physical and logical coupling enables the portable treatment controller 120 to both communicate with and, in some instances, control the operation of specialized devices. These specialized devices may include physiological sensors, therapy delivery devices, and computer networking devices.

According to various examples, the hardware and software components of the interfaces 202, 206 and 212 employ a variety of coupling and communication techniques. In some examples, the interfaces 202, 206 and 212 use leads, cables or other wired connectors as conduits to exchange data between the portable treatment controller 120 and specialized devices. In other examples, the interfaces 202, 206 and 212 communicate with specialized devices using wireless technologies such as radio frequency or infrared technology. The software components included in the interfaces 202, 206 and 212 enable the power conserving processor arrangement 200 to communicate with specialized devices. These software components may include elements such as objects, executable code and populated data structures. Together, these hardware and software components provide interfaces through which the power conserving processor arrangement 200 can exchange information with the specialized devices. Moreover, in at least some examples where one or more specialized devices communicate using analog signals, the interfaces 202, 206 and 212 can include components configured to convert analog information into digital information, and vice-versa.

As discussed above, the system interface components 202, 206 and 212 shown in the example of FIG. 2 support different

types of specialized devices. For instance, the components of the sensor interface 212 couple the power conserving processor arrangement 200 to one or more physiological sensors such as a body temperature sensors, respiration monitors and dry-capacitive ECG sensing electrodes. It should be appreciated that other types of ECG sensing electrodes may be used, as the present invention is not limited to any particular type of ECG sensing electrode. The components of the therapy delivery interface 202 couple one or more therapy delivery devices, such as capacitors and defibrillator electrodes, to the power conserving processor arrangement 200. In addition, the components of the network interface 206 couple the power conserving processor arrangement to a computer network via a networking device, such as a bridge, router or hub. The network interface 206 may support a variety of standards and protocols, examples of which include USB, TCP/IP, Ethernet, Wireless Ethernet, Bluetooth, ZigBee, M-Bus, IP, IPV6, UDP, DTN, HTTP, FTP, SNMP, CDMA, NMEA and GSM. To ensure data transfer is secure, in some examples, the portable treatment controller 200 can transmit data via the network interface 206 using a variety of security measures including, for example, TLS, SSL or VPN. In other examples, the network interface 206 includes both a physical interface configured for wireless communication and a physical interface configured for wired communication.

The user interface 208 shown in FIG. 2 includes a combination of hardware and software components that allow the portable treatment controller 200 to communicate with an external entity, such as a user. These components are configured to receive information from actions such as physical movement, verbal intonation or thought processes. In addition, the components of the user interface 208 can provide information to external entities. Examples of the components that may be employed within the user interface 208 include keyboards, mouse devices, trackballs, microphones, electrodes, touch screens, printing devices, display screens and speakers.

The LifeVest® wearable cardioverter defibrillator can monitor a patient's ECG signals, detect various cardiac arrhythmias, and provide life saving defibrillation treatment to a patient suffering a treatable form of cardiac arrhythmia such as Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT).

Applicants have appreciated that such a medical monitoring and treatment device can be configured to perform a variety of different types of cardiac pacing to treat a wide variety of different cardiac arrhythmias, such as bradycardia, tachycardia, an irregular cardiac rhythm, or asystole. Applicants have further appreciated that, in other embodiments, a medical monitoring and treatment device can be configured to perform pacing to treat pulseless electrical activity. In accordance with an aspect of the present invention, the device can be configured to pace the heart of the patient at a fixed energy level and pulse rate, to pace the heart of the patient on demand with a fixed energy level and an adjustable rate responsive to the detected intrinsic activity level of the patient's heart, or to pace the heart of the patient using capture management with an adjustable energy level and rate responsive to the detected intrinsic activity level of the patient's heart and the detected response of the patient's heart. The various types of pacing may be applied to the patient externally by one or more of the therapy electrodes 114a, 114b (FIG. 1). Various types of pacing that can be performed by a medical monitoring and treatment device, such as the LifeVest® wearable cardioverter defibrillator, can include asynchronous pacing at a fixed rate and energy, pacing on demand at a variable rate and

fixed energy, and capture management pacing with an adjustable rate and adjustable energy level.

In some embodiments, the medical monitoring and treatment device is configured to periodically assess the level of discomfort of the patient during pacing operation. In these 5 embodiments, responsive to determining that the patient's discomfort level exceeds a threshold, the device attempts to adjust the attributes of the pacing activity to lessen the discomfort experienced by the patient.

In one embodiment, the medical monitoring and treatment device provides a user interface through which the device receives information descriptive of the discomfort level experienced by a patient. Should this information indicate that the level of discomfort has transgressed a threshold level, the device adjusts characteristics of the pacing operation in an attempt to decrease the level of discomfort. 15

In another embodiment, the medical monitoring and treatment device assesses the level of discomfort of the patient by monitoring and recording the patient's movement before, during, and after administration of a pacing pulse. The device may monitor the patient's movement using a variety of instrumentation including, for example, one or more accelerometers, audio sensors, etc. To assess the level of discomfort experienced by the patient during pacing pulses, the device may analyze the recorded history of the patient's movement and identify correlations between changes in the patient's movement and the pacing pulse. Strong correlations between pacing pulses and sudden patient movement, which may be representative of a flinch, and strong correlations between pacing pulses and a sudden stoppage of movement, may indicate that a patient is experiencing discomfort. Correlations having a value that transgresses a threshold value may be deemed to indicate discomfort and may cause the device to adjust the characteristics of a pacing pulse. 25

In other embodiments, the device adjusts the characteristics of the pacing operation to lessen the discomfort level of the patient. The characteristics of the pacing operation that may be adjusted include, for example, the energy level of pacing pulses, the width of the pacing pulses, and the rate of the pacing pulses. In some embodiments, the device monitors the cardiac activity of the patient during this adjustment process to ensure that the pacing operation continues to effectively manage cardiac function. In these embodiments, the device may revert the characteristics of the pacing operation to their previous settings, should the pacing operation become ineffective. 35

1. Fixed Rate and Energy Pacing

In accordance with an aspect of the present invention, a medical monitoring and treatment device, such as the Life-Vest® wearable cardioverter defibrillator, can be configured to pace the heart of a patient at a fixed rate and fixed energy in response to various types of cardiac arrhythmias. Examples of these cardiac arrhythmias include bradyarrhythmia, a lack of sensed cardiac activity (spontaneous or post shock asystole) and pulseless electrical activity. In some cases, these cardiac arrhythmias may occur before or after one or more defibrillation shocks. For example, the device may be configured to provide pulses at a fixed energy level, a fixed pulse width, and a fixed frequency in response to detection of any of the above-noted events by the ECG sensing electrodes 112. The energy level of the pacing pulses may be set to a fixed value by applying a desired current waveform for a determined duration of time by one or more of the therapy electrodes 114a, 114b. The maximum current level of the current waveform may be set to a value between approximately 0 mAmps to 200 mAmps, the pulse width may be set to a fixed value between approximately 0.05 ms to 2 ms, and the fre- 65

quency of the pulses may be set to a fixed value between approximately 30 pulses per minute (PPM) to approximately 200 PPM. In accordance with one embodiment, a 40 ms square wave pulse is used. Exemplary pacing current waveforms, including a 40 ms constant current pulse, a 5 ms constant current pulse, and a variable current pulse are shown in FIG. 3.

During pacing operation of the medical monitoring and treatment device, the device may periodically pause for a period of time to evaluate the patient via the ECG sensing electrodes to determine whether a normal sinus rhythm has returned. Where the device detects a normal sinus rhythm, the device may discontinue the application of pacing pulses and simply continue monitoring the patient's physiological signals, such as the patient's ECG, temperature, pulse oxygen level, etc.

During an initial fitting of the medical monitoring and treatment device, the level of current, the pulse width, and the frequency of the pulses may be set to an appropriate level based on the input of a medical professional (such as the patient's cardiologist) and the physiological condition of the patient (e.g., based on the patient's normal resting heart rate, the patient's thoracic impedance, etc.) Alternatively, the level of current, the pulse width, and the frequency of the pulses may simply be set to an appropriate value based on typical impedance values for an adult or child, and typical resting heart rates for an adult or child.

It should be appreciated that because pacing at a fixed rate may interfere with the patient's own intrinsic heart rate, the device can be configured to perform such fixed rate and energy pacing only in the event of a life-threatening Bradycardia, a lack of any detected cardiac activity following shock, or in response to pulseless electrical activity following shock.

2. Demand (Adjustable Rate) Pacing

In accordance with an aspect of the present invention, a medical monitoring and treatment device, such as the Life-Vest® wearable cardioverter defibrillator, can also be configured to pace the heart of a patient at a variable rate and a fixed energy in response to various types of cardiac arrhythmias, including a bradyarrhythmia (i.e., an excessively slow heart rate), tachycardia (i.e., an excessively fast heart rate), an erratic heart rate with no discernible regular sinus rhythm, a lack of sensed cardiac activity (asystole), and pulseless electrical activity. Some of these cardiac arrhythmias may occur following one or more defibrillation shocks.

As known to those skilled in the art, pacing at a fixed rate and energy may not be appropriate to the particular type of cardiac arrhythmia of the patient, and even where the rate and energy level is appropriate, pacing at a fixed rate can result in competition between the rate at which the pacing pulses are being applied and the intrinsic rhythm of the patient's heart. For example, pacing at a fixed rate may result in the application of a pacing pulse during the relative refractory period of the normal cardiac cycle (a type of R wave on a T wave effect) that could promote ventricular tachycardia or ventricular fibrillation. To overcome some of the disadvantages of fixed rate and energy pacing, the medical monitoring and treatment device can be configured to perform demand pacing, wherein the rate of the pacing pulses may be varied dependent on the physiological state of the patient. For example, during demand pacing, the device can deliver a pacing pulse only when needed by the patient. In general, during the demand mode of pacing, the device searches for any intrinsic cardiac activity of the patient, and if a heart beat is not detected within a designated interval, a pacing pulse is delivered and a timer is set to the designated interval. Where the designated interval

expires without any detected intrinsic cardiac activity of the patient, another pacing pulse is delivered and the timer reset. Alternatively, where an intrinsic heart beat of the patient is detected within the designated interval, the device resets the timer and continues to search for intrinsic cardiac activity.

FIG. 4 helps to illustrate some of the aspects of demand pacing and the manner in which demand pacing can be performed by the medical monitoring and treatment device. As illustrated in FIG. 4, the device may have a variable pacing interval 410 corresponding to the rate at which pacing pulses are delivered to the patient in the absence of any detected intrinsic cardiac activity detected by the ECG sensing electrodes 112 and ECG monitoring and detection circuitry. For example, the rate at which pulsing paces are to be delivered to the patient (referred to as the “base pacing rate” herein) may be set at 60 PPM and therefore, the corresponding base pacing interval 410 would be set to 1 second.

The medical monitoring and treatment device may also have a hysteresis rate (not shown in FIG. 4) corresponding to the detected intrinsic heart rate of the patient below which the device performs pacing. According to some embodiments, the hysteresis rate is a configurable parameter that is expressed as a percentage of the patient’s intrinsic heart rate. In the above example, the hysteresis rate may correspond to 50 beats per minute (BPM). In this example, if the intrinsic heart rate of the patient fell to 50 BPM or below (e.g., more than approximately 1.2 seconds between detected beats), the device would generate and apply a pacing impulse to the patient.

During application of a pacing pulse to the body of a patient and a short time thereafter, the medical monitoring and treatment device may intentionally blank out a portion of the ECG signals being received by the ECG monitoring and detection circuitry to prevent this circuitry (e.g., amplifiers, A/D converters, etc.) from being overwhelmed (e.g., saturated) by the pacing pulse. This may be performed in hardware, software, or a combination of both. This period of time, referred to herein as “the blanking interval” 420 may vary (e.g., between approximately 30 ms to 200 ms), but is typically between approximately 40 ms to 80 ms in duration.

In addition to the blanking interval 420, the medical monitoring and treatment device can have a variable refractory period 430 that may vary dependent upon the base pacing rate. The refractory period 430 corresponds to a period of time in which signals sensed by the ECG sensing electrodes 112 and the ECG monitoring and detection circuitry are ignored, and includes the blanking interval. The refractory period 430 allows any generated QRS complexes or T waves induced in the patient by virtue of the pacing pulse to be ignored, and not interpreted as intrinsic cardiac activity of the patient. For example, where the base pacing rate is set to below 80 PPM, the refractory period might correspond to 340 ms, and where the base pacing rate is set above 90 PPM, the refractory period might correspond to 240 ms. For typical applications, the refractory period is generally between about 150 ms and 500 ms.

In accordance with an aspect of the present invention, the sensitivity of the ECG monitoring and detection that is performed by the medical monitoring and treatment device may also be varied to adjust the degree by which the ECG sensing electrodes and associated ECG monitoring and detection circuitry can detect the patient’s intrinsic cardiac activity. For example, where the amplitude of certain discernable portions (e.g., an R-wave) of a patient’s intrinsic ECG signal is below that typically encountered, the voltage threshold over which this discernable portion can be detected as belonging to an ECG signal (and not attributed to noise or other factors) may

be lowered, for example from 2.5 mV to 1.5 mV, to better detect the patient’s intrinsic cardiac activity. For instance, during an initial fitting of the medical monitoring and treatment device, the sensitivity threshold of the device may be reduced to a minimal value (e.g., 0.4 mV) and the patient’s intrinsic ECG signals may be monitored. The sensitivity threshold may then be incrementally increased (thereby decreasing the sensitivity of the device) and the patient’s intrinsic ECG signals monitored until these ECG signals are no longer sensed. The sensitivity threshold may then be incrementally decreased (thereby increasing the sensitivity of the device) until the patient’s intrinsic ECG signals are again sensed, and the sensitivity threshold of the device may be set to approximately half this value.

As with fixed energy and rate pacing, the device may be configured to provide pulses at a fixed energy level and a fixed pulse width in response to detection of any of the above-noted events by the ECG sensing electrodes 112 and the ECG monitoring and detection circuitry. The maximum current level of the current waveform may be set to a value between approximately 10 mAmps to 200 mAmps, the pulse width may be set to a fixed value between approximately 20 ms to 40 ms, and the base rate of the pulses may be set to a fixed value between approximately 30 pulses per minute (PPM) to approximately 200 PPM, although the actual rate of the pacing pulses can vary based upon the intrinsic cardiac activity of the patient. In accordance with one embodiment, a 40 ms constant current pulse is used, and the current level is set to a fixed value based upon the input of a medical professional, such as the patient’s cardiologist and the physiological condition of the patient. The base pacing rate and the hysteresis rate may also be set based upon the input of the patient’s cardiologist (or other medical professional) and the physiological condition of the patient, and the blanking interval and refractory period set to an appropriate time interval based upon the base pacing rate and/or the hysteresis rate.

Although the base pacing rate may be set to a particular value based on the physiological condition of the patient and input from a medical profession, the medical monitoring and treatment device can include a number of different pacing routines to respond to different cardiac arrhythmias, such as bradycardia, tachycardia, an erratic heart rate with no discernable regular sinus rhythm, asystole, or pulseless electrical activity. These pacing routines may be implemented using a variety of hardware and software components and embodiments are not limited to a particular configuration of hardware or software. For instance, the pacing routines may be implemented using an application-specific integrated circuit (ASIC) tailored to perform the functions described herein.

A. Bradycardia

As discussed above, where Bradycardia is detected and the intrinsic cardiac rate of the patient is below that of the hysteresis rate, the medical monitoring and treatment device will pace the patient at the pre-set base pacing rate. During this time, the device will continue to monitor the patient’s intrinsic heart rate and will withhold pacing pulses in the event that an intrinsic heart beat is detected within designated interval corresponding to the hysteresis rate. This type of on demand pacing is frequently termed “maintenance pacing.”

B. Tachycardia

For responding to tachycardia, the medical monitoring and treatment device may additionally include another pacing rate, termed an “anti-tachyarrhythmic pacing rate” herein, above which the device will identify that the patient is suffering from tachycardia, and will pace the patient in a manner to bring the patient’s intrinsic heart back toward the base racing rate. For example, the device may employ a technique known

as overdrive pacing wherein a series of pacing pulses (e.g., between about 5 and 10 pacing pulses) are delivered to the patient at a frequency above the intrinsic rate of the patient in an effort to gain control of the patient's heart rate. Once it is determined that the device is in control of the patient's heart rate, the rate (i.e., the frequency) of the pulses may be decremented, for example by about 10 ms, and another series of pacing pulses delivered. This delivery of pulses and the decrease in frequency may continue until the detected intrinsic cardiac rate of the patient is below the anti-tachyarrhythmic pacing rate, or at the base pacing rate. This type of pacing is frequently termed "overdrive pacing" or "fast pacing."

C. Erratic Heart Rate

For responding to an erratic heart rate, the medical monitoring and treatment device may perform a type of pacing that is similar to a combination of maintenance pacing and overdrive pacing discussed above. For example, where the medical monitoring and treatment device detects an erratic heart rate with no discernable sinus rhythm, the device may deliver a series of pacing pulses (e.g., between about 5 and 10 pacing pulses) to the patient at a particular frequency. This frequency may be one that is above a lower frequency of a series of detected intrinsic beats of the patient's heart and below an upper frequency of the detected intrinsic beats of the patient's heart. After delivering the series of pulses, the device may monitor the patient's heart to determine if it has synchronized to the rate of the series of delivered pulses. Where the intrinsic rate of the patient's heart is still erratic, the device may increase the frequency of the series of pulses and deliver another series. This may continue until it is established that the patient's heart is now in a more regular state. Upon determining that the patient's heart is now in a more regular state, the device may perform maintenance pacing if it is determined that the patient's intrinsic heart rate is too low as discussed in section 2A above, or perform pacing at a decremented rate in the manner discussed in section 2B above, if such is warranted.

D. Asystole or Pulseless Electrical Activity

For responding to asystole or a detected condition of pulseless electrical activity, the medical monitoring and treatment device may perform maintenance pacing similar to that described in section 2A above. This type of pacing would be performed after a series of one or more defibrillating shocks that attempt to restore a normal sinus rhythm to the heart of the patient.

In each of the above types of pacing, the medical monitoring and treatment device may be configured to perform a particular type of pacing only after a programmable delay after such cardiac arrhythmias are detected, or after a programmable period of time after one or more defibrillating shocks are delivered.

3. Capture Management

In accordance with an aspect of the present invention, a medical monitoring and treatment device, such as the Life-Vest® wearable cardioverter defibrillator, can also be configured to pace the heart of a patient using capture management with an adjustable energy level and an adjustable rate in response to various types of cardiac arrhythmias. The various types of cardiac arrhythmias can include a bradycardia, tachycardia, an erratic heart rate with no discernable regular sinus rhythm, a lack of sensed cardiac activity (asystole) following or independent of one or more defibrillation shocks, a life-threatening Bradyarrhythmia following one or more defibrillation shocks, or pulseless electrical activity following one or more defibrillation shocks.

As known to those skilled in the art, capture management refers to a type of pacing in which the energy level of pacing

pulses and the rate of delivery of those pacing pulses may be varied based upon the detected intrinsic activity level of the patient's heart and the detected response of the patient's heart to those pacing pulses. In cardiac pacing, the term "capture" is used to refer to the response of a patient's heart to a pulse of energy which results in ventricular depolarization. In cardiac pacing, it is desirable to limit the amount of energy in each pulse to a minimal amount required for capture; thereby minimizing the amount of discomfort associated with external pacing.

In general, the manner in which the medical monitoring and treatment device can perform capture management pacing is similar to that of demand pacing described above, in that it may adjust the rate at which pacing pulses are delivered based upon the detected intrinsic rate of cardiac activity of the patient. The sensitivity of the device to the patient's ECG may be adjusted in a similar manner to that described above with respect to demand pacing. Further, capture management pacing may be used to treat the same types of cardiac arrhythmias as the demand pacing described above, such as bradycardia, tachycardia, an erratic heart rate with no discernable sinus rhythm, asystole, or pulseless electrical activity.

However, in contrast to a device that performs demand pacing, a device that is configured to perform capture management pacing will typically have a refractory period **430** (see FIG. 4) that is significantly shorter than a device configured to perform demand pacing. Indeed, when using capture management pacing, there may be no refractory period **430** at all, but only a blanking interval **420**. Alternatively, where there is a refractory period **430**, the refractory period **430** may be similar in duration to the blanking interval **420**. As would be appreciated by those skilled in the art, this is because during capture management pacing, the response of the patient's heart is monitored by the ECG sensing electrodes **112** and ECG monitoring and detection circuitry to detect whether the delivered pulse of energy resulted in capture. For this reason, while the ECG monitoring and detection circuitry may be switched off or effectively disabled during the delivery of energy pulses, it is important that it be switched back on or otherwise enabled shortly thereafter to detect whether the delivered pulse resulted in capture. In one embodiment in which a 40 ms constant current pulse is used, the blanking interval **420** may be set to approximately 45 ms to avoid saturation of the ECG monitoring and detection circuitry, but ensure that any intrinsic electrical activity of the patient's heart that was induced by the pacing pulse is detected.

During capture management pacing, the medical monitoring and treatment device can deliver a pulse of energy at a determined energy level and monitor the patient's response to determine if capture resulted. Where it is determined that the delivered pulse did not result in capture, the energy level of the next pulse may be increased. For example, where the device is a medical monitoring and treatment device that is external to the patient, the initial setting may be configured to provide a 40 ms rectilinear and constant current pulse of energy at a current of 40 mAmps, and increase the amount of current in increments of 2 mAmps until capture results. The next pacing pulse may be delivered at increased current relative to the first pacing pulse and at a desired rate relative to the first pacing pulse in the absence of any detected intrinsic cardiac activity of the patient. Where the next pacing pulse does not result in capture, the energy may be increased until capture is detected. The medical monitoring and treatment device may then continue pacing at this energy level and at a desired rate in the absence of any detected intrinsic cardiac activity of the patient. During this period of time, the device monitors the patient's cardiac response to the pacing pulses,

and may increment the energy level further, should it be determined over one or more subsequent pulses that capture did not result.

In an alternative configuration, the medical monitoring and treatment device may apply a series of pulses at an initial energy level and rate, and monitor the patient's response to determine if capture resulted. Where capture did not result, or where capture resulted in response to some of the pulses, but not all, the device may increase the energy of a next series of pulses until capture results for each pulse.

Alternatively, the device may be configured to identify a minimum amount of energy that results in capture during capture management pacing. Where it is determined that the delivered pulse did result in capture, the energy level of the next pulse may be decreased. For example, where the device is a medical monitoring and treatment device that is external to the patient, the initial setting may be configured to provide a 40 ms constant current pulse of energy at a current of 70 mAmps. Where it is determined that the delivered pulse resulted in capture, subsequent pacing pulses may be delivered and decreased in increments of 5 mAmps and at a desired rate relative to the first pacing pulse in the absence of any detected intrinsic cardiac activity of the patient until capture is no longer achieved. Where the next pacing pulse does not result in capture, the energy setting may be increased to the last current known to produce a pulse resulting in capture, and then delivering a pulse at the higher energy setting, thus delivering the minimal amount of energy required for capture. The medical monitoring and treatment device may then continue pacing at this energy level and at a desired rate in the absence of any detected intrinsic cardiac activity of the patient. During this period of time, a similar routine may be re-performed at predetermined intervals to ensure that the minimum amount of energy is being delivered for capture. In addition, during this period of time, the device monitors the patient's cardiac response to the pacing pulses, and may increase the energy level should it be determined over one or more subsequent pulses that capture did not result.

It should be appreciated that in the various embodiments described above, an external medical monitoring and treatment device has been described which may not only provide life saving defibrillation or cardioversion therapy, but may also provide a wide variety of different pacing regimens. Because the medical monitoring and treatment device can monitor a patient's intrinsic cardiac activity, the patient's thoracic impedance, and other physiological parameters of the patient, the device may be configured to recommend various settings to a medical professional for review and approval. The various settings that may be recommended may include a recommended base pacing rate, a recommended hysteresis rate, a recommended anti-tachyarrhythmic pacing rate, a recommended energy level (or initial energy level if capture management is used), a recommended blanking interval, and/or refractory period, and a recommended sensitivity threshold. In the case of a medical monitoring and treatment device such as the LifeVest® cardioverter defibrillator, this initial recommendation may be performed when the patient is being fitted for and trained on the use of the device.

Although the ability to recommend such settings to a medical professional for their review and approval is particularly well suited to a medical monitoring and treatment device, such as the LifeVest® cardioverter defibrillator, such functionality could also be implemented in an Automated External Defibrillator (AED) or an Advanced Life Support (ALS) type of defibrillator, such as the M Series defibrillator, R Series ALS defibrillator, R Series Plus defibrillator, or E Series defibrillator manufactured by the ZOLL Medical Cor-

poration of Chelmsford Mass. It should be appreciated that monitoring the patient's intrinsic cardiac activity and other physiological parameters and making recommendations to a trained medical professional for their review and approval (or possible modification) could reduce the amount of time that is spent manually configuring such devices prior to use on the patient.

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.

What is claimed is:

1. A non-invasive bodily-attached ambulatory medical monitoring and treatment device comprising:
 - at least one electro-cardiogram (ECG) sensing electrode configured to be disposed on a patient;
 - at least one therapy electrode configured to be disposed on the patient;
 - a treatment controller, coupled to the at least one ECG sensing electrode and the at least one therapy electrode, configured to sense a cardiac condition of the patient, to implement at least one pacing routine corresponding to the sensed cardiac condition, and to detect a discomfort of the patient during the at least one pacing routine.
2. The device of claim 1, wherein the treatment controller is further configured to adjust at least one characteristic of the at least one pacing routine in response to the detected discomfort of the patient.
3. The device of claim 2, wherein, the at least one characteristic of the at least one pacing routine includes at least one of an energy level of pacing pulses, a width of the pacing pulses, and a rate of the pacing pulses.
4. The device of claim 1, wherein the treatment controller comprises a user interface configured to receive information from the patient descriptive of the discomfort.
5. The device of claim 4, wherein the treatment controller is configured to detect the discomfort based on the information from the patient.
6. The device of claim 4, wherein the user interface includes at least one patient response element, and wherein the user provides the information descriptive of the discomfort via the at least one response element.
7. The device of claim 4, wherein the information descriptive of the discomfort comprises a voice signal from the patient.
8. The device of claim 4, wherein the at least one patient response element comprises at least one button.
9. The device of claim 4, wherein the at least one patient response element comprises a touch screen.
10. The device of claim 4, wherein the at least one patient response element comprises a microphone.
11. The device of claim 4, wherein the treatment controller is further configured to adjust at least one characteristic of the at least one pacing routine in response to the information from the patient.
12. The device of claim 1, further comprising at least one motion sensor in communication with the treatment controller to detect motion of the patient during the at least one pacing routine.
13. The device of claim 12, wherein the at least one motion sensor includes at least one of an accelerometer and an audio sensor.

19

14. The device of claim 12, wherein the treatment controller is further configured to monitor the detected motion of the patient during the at least one pacing routine, and to detect the discomfort of the patient based on the detected motion.

15. The device of claim 14, wherein the treatment controller is further configured to adjust at least one characteristic of the at least one pacing routine in response to the detected discomfort.

16. The device of claim 14, wherein the at least one pacing routine includes at least one pacing pulse, and wherein the treatment controller is further configured to monitor the detected motion of the patient before, during, and after the at least one pacing pulse.

17. The device of claim 16, wherein the treatment controller is further configured to adjust at least one characteristic of the at least one pacing routine in response to the detected discomfort.

18. The device of claim 1, wherein the cardiac condition of the patient comprises at least one of Bradycardia, tachycardia, asystole, pulseless electrical activity, and erratic heart rate.

19. The device of claim 1, wherein the at least one pacing routine comprises at least one of including fixed rate and fixed energy pacing, adjustable rate pacing, and capture management pacing.

20

20. The device of claim 1, wherein the at least one pacing routine comprises a plurality of pacing routines, the plurality of pacing routines including at least two of fixed rate and fixed energy pacing, adjustable rate pacing, and capture management pacing.

21. A non-invasive bodily-attached ambulatory medical monitoring and treatment device comprising:

at least one electro-cardiogram (ECG) sensing electrode configured to be disposed on a patient;

at least one therapy electrode configured to be disposed on the patient;

a treatment controller, coupled to the at least one ECG sensing electrode and the at least one therapy electrode, configured to sense a cardiac condition of the patient, to implement at least one pacing routine corresponding to the sensed cardiac condition, to receive information indicative of patient motion during the at least one pacing routine, and to assess a level of discomfort of the patient during the at least one pacing routine.

22. The device of claim 21, wherein the device further includes at least one motion sensor to provide the information indicative of patient motion to the treatment controller.

23. The device of claim 21, wherein the at least one motion sensor includes at least one of an accelerometer and an audio sensor.

* * * * *

专利名称(译)	具有外部起搏的医疗监测和治疗装置		
公开(公告)号	US9320904	公开(公告)日	2016-04-26
申请号	US14/610600	申请日	2015-01-30
[标]申请(专利权)人(译)	卓尔医学产品公司		
申请(专利权)人(译)	ZOLL医疗公司		
当前申请(专利权)人(译)	ZOLL医疗公司		
[标]发明人	WHITING JASON T KAIB THOMAS E CARLSON RACHEL H FRANK GREGORY R		
发明人	WHITING, JASON T. KAIB, THOMAS E. CARLSON, RACHEL H. FRANK, GREGORY R.		
IPC分类号	A61N1/00 A61B5/00 A61N1/39 A61N1/362 A61N1/365 A61B5/0408 A61N1/04 A61B5/046		
CPC分类号	A61N1/36592 A61B5/046 A61B5/04085 A61B5/6831 A61N1/046 A61N1/0484 A61N1/362 A61N1/3625 A61N1/3925 A61N1/3987 A61B2562/17 A61N1/3621 A61N1/371		
优先权	61/653889 2012-05-31 US		
其他公开文献	US20150148854A1		
外部链接	Espacenet USPTO		

摘要(译)

提供了一种具有起搏的非侵入性身体附着的可移动医疗监测和治疗装置。非侵入性移动起搏装置包括电池，耦合到电池的至少一个治疗电极，存储指示患者心脏活动的信息的存储器，以及耦合到存储器和至少一个治疗电极的至少一个处理器。所述至少一个处理器被配置为识别所述信息内的心律失常，并且执行至少一个起搏例程以治疗所识别的心律不齐。

